Key Facts on Outlook: * Full-year FY26 revenue growth projected at 20% CAGR, aiming for over INR 1,500 crores in H2. * EBITDA margin guidance maintained at 16.5% to 17.5% for FY26. * Strong order book exceeding INR 11,000 crores, targeting INR 4,000-4,500 crores in new orders
* Planned 2,000 bed expansion over 3-4 years. * New Noida 550-bed facility commencing operations soon. * New Ranchi 110-bed hospital operationalized July 2025. * Expected ARPOB (Average Revenue Per Occupied Bed) growth above inflation. * Q1 FY26 EBITDA margin improved to 24.3%. * Q1 FY26 PAT margin improved to 15.1%. Global Health
* Sales Outlook: Global Health Limited (Medanta) is poised for substantial capacity expansion with the 110-bed Ranchi hospital operational since July 2025 and the 550-bed Noida facility commencing operations soon, starting with 300 beds. The company also plans to add 100 beds in Patna and Lucknow, and has a broader pipeline
* Sales Growth Outlook: Expects to surpass earlier 17.5% annual growth guidance for the year. * Margin Outlook: Anticipates EBITDA margins to improve from Q3 onwards, aiming to exceed last year's EBITDA with a focus on 50-100 basis points improvement. * Capacity Expansion: Two new pre-engineered building (PEB) lines (Andhra
* Revenue Growth Outlook: Targeted above 17.5%, potentially reaching 20% for FY26. * EBITDA Margin Outlook: Expected to improve from 8.3% (1QFY26), aiming to surpass previous year’s EBITDA and achieve 10%+ from Q3 onwards. * Capacity Expansion: Increasing from 161,000 MTPA to approximately 200,000 MTPA by August 2025.
* Bio-Fuels Business: Expected to continue strong growth, aligning with the government's 20% blending target by 2025, with potential to increase to 25-30% by 2030. * Value-Added Performance Chemicals: Anticipates over 150% volume/value contribution growth in the foreseeable future, maintaining reasonable contribution levels. * Potable Spirits: Expects significantly better growth
Key Facts on Outlook: * **Overall:** Strong Q1 FY26 with net revenue up 7% and PAT up 21%. Expects continued growth across segments, supported by strategic initiatives. * **Bio-Fuels:** Top line up 45% (Q1 FY26). Expected sustained double-digit growth, driven by increased consumption, penetration, and potential higher blending mandates (20% by FY26,
* Overall FY26 Top-line Growth: Projected in "early teens." * Overall FY26 Profit: Expected to be maintained as per prior guidance. * Crop Protection (EBIT Margin): Targeted at "close to 28% to 30%." * Crop Protection (Sales): New product Ashitaka has a "theoretical potential of Rs. 200 crores"
Key Facts on Outlook & Guidance * Sales Outlook (FY26): Company expects top-line growth in "early teens." * Profit Outlook (FY26): Anticipates maintaining profit levels. * Astec LifeSciences: Targeting EBITDA break-even in FY26, aiming for Rs. 500 crore turnover, with CDMO revenue exceeding Rs. 300 crore and growing over 30% annually.
Key Facts: * The provided PDF is a formal notification from Quick Heal Technologies Ltd. * It announces the availability of the Q1 FY26 investor/analyst call transcript. * The transcript itself, containing detailed sales and margin outlook, is linked externally. * Specific guidance on sales and margins cannot be extracted directly from this
* Company: Quick Heal Technologies Ltd. * Document Type: Investor/Analyst Call Transcript for Q1 FY2025-26. * Call Date: Friday, August 8, 2025. * Transcript Release Date: August 15, 2025. * Availability: Accessible via company website link. * Guidance Note: Specific sales and margin guidance details are contained within the full transcript, not this cover letter.
* Sales/Volume: Anticipates 8-9% volume growth for FY26, driven by a strong order book and regained market share across segments. Exports, particularly Hi-Tech and flow control products, are projected to see a significant upswing from 2026. * Margin/Profitability: Forecasts a sequential upswing in margins for Q2 and Q3 FY26. The